The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer

HIGHLIGHTS

• who: Philip Bredin from the The Bloomberg-Kimmel Institute of Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA have published the research work: The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer, in the Journal: (JOURNAL)
• what: Beta diversity refers to the difference between communities or samples, and is less frequently referred to in the studies described in this Article. In this study, a multivariate analysis was conducted to account for baseline factors that associate with poorer OS such as advanced age, prior . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.